Pfizer, Inc. P/E Ratio 2007–2025
Pfizer, Inc. reported 17.41 of price-to-earnings ratio for fiscal 2025. That was 4.3% higher than fiscal 2024. Compared with fiscal 2020, the change was +3.5%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 17.41 | +4.3% |
| FY 2024 | 16.68 | -74.3% |
| FY 2023 | 65.02 | +768.3% |
| FY 2022 | 7.49 | -36.9% |
| FY 2021 | 11.88 | -29.4% |
| FY 2020 | 16.83 | +69.2% |
| FY 2019 | 9.95 | -34.9% |
| FY 2018 | 15.29 | +122.9% |
| FY 2017 | 6.86 | -59.4% |
| FY 2016 | 16.89 | -0.9% |
| FY 2015 | 17.05 | +30.0% |
| FY 2014 | 13.12 | +136.5% |
| FY 2013 | 5.55 | -19.1% |
| FY 2012 | 6.86 | -21.2% |
| FY 2011 | 8.70 | +3.4% |
| FY 2010 | 8.41 | +14.8% |
| FY 2009 | 7.32 | +5.6% |
| FY 2008 | 6.94 | -19.0% |
| FY 2007 | 8.57 | — |
Source: Pfizer, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open PFE 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Pfizer, Inc. reported 17.41 of price-to-earnings ratio for fiscal 2025. That was 4.3% higher than fiscal 2024. Compared with fiscal 2020, the change was +3.5%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Pfizer, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freePfizer, Inc. — frequently asked questions
What is Pfizer, Inc.'s price-to-earnings ratio?
Pfizer, Inc. (PFE) reported price-to-earnings ratio of 17.41 for fiscal year 2025, per its SEC filings.
How has Pfizer, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2007 and 2025, PFE's price-to-earnings ratio grew at roughly 4.0% per year (compound annual rate), from 8.57 to 17.41.
Where does this data come from?
Figures are computed from Pfizer, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More PFE financial history
Full PFE fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →